A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(31 sites)

China

Research Site, Beijing

Research Site, Changchun

Research Site, Changsha

Research Site, Changzhou

Research Site, Chengdu

Research Site, Chongqing

Research Site, Dongyang

Research Site, Guangzhou

Research Site, Haikou

Research Site, Hangzhou

Research Site, Harbin